New Report: TELUS Health's inaugural Pharmacy Trends market analysis unveils Canadian pharmacies poised for $1.9B tech-driven transformation
Specialty pharmacy market expected to exceed $20B with over 10,000 licensed pharmacies filling critical healthcare gaps nationwide
Advanced pharmacy systems enabling seamless collaboration and digital technology putting prescription management at patients' fingertips
TORONTO, May 20, 2025 /CNW/ - Canada's pharmacy sector is undergoing a revolution to meet changing healthcare needs, according to TELUS Health's inaugural Pharmacy Trends Report: The Future of Pharmacy in Canada: Five Trends Shaping Canada's Healthcare Landscape in 2025. With the automated central fill pharmacy market projected to reach $1.9 billion by 2030 and Canada's specialty pharmacy market expected to exceed $20 billion, technological automation is enabling pharmacists to step into expanded healthcare roles, fundamentally changing how people in Canada access primary care services.
"We're witnessing a seismic shift in Canadian healthcare delivery," said Ratcho Batchvarov, Vice-president, Provider Solutions, TELUS Health. "Our first Pharmacy Trends report reveals that pharmacies are rapidly evolving into comprehensive healthcare hubs, bridging critical gaps in primary care access. With the specialty pharmacy market set to surge beyond $20 billion and automation driving a $1.9 billion revolution in central fill services, we're not just talking about incremental change – this is a fundamental reimagining of community healthcare. Pharmacists have been advancing their role as frontline care providers, leveraging cutting-edge technology to offer more accessible, efficient and personalized care. This transformation is creating a more resilient and responsive healthcare ecosystem for all Canadians."
The Pharmacy Trends Report provides valuable insights on how the Canadian pharmacy sector is evolving, enabling both pharmacists and pharmacy managers to identify opportunities for improved efficiencies in their practice and enhance patient care. Three notable trends from this first report include:
Putting an expanded scope of practice into action: As millions of people in Canada struggle to find a family doctor, the nation's network of more than 10,000 licensed pharmacies is stepping up to fill critical healthcare gaps. These locations offer essential medical services, from vaccinations to prescribing medications for minor ailments.
Patients see their pharmacists 1.5 to 10 times more than they see their primary care physician.
Enhancing collaboration and streamlining operations: technology solutions can empower pharmacists to deliver their services in a way that's comfortable to them, and patients can access consistent services and care, regardless of where they go:
Centralized prescription fulfillment reduces errors and administrative burdens, allowing pharmacists to focus on patient care. Over a quarter of community pharmacists in one survey noted their dissatisfaction with the daily volume of prescriptions to be processed.
Advanced Pharmacy Management Systems allow pharmacists to collaborate seamlessly with other healthcare providers, ensuring patients receive consistent, well-coordinated care across all touchpoints.
Specialty drug claims have tripled over the past 15 years, rising from 10.4 per cent to 32.8 per cent of total pharmacy claims. This dramatic increase means pharmacists must now manage more complex medication regimens while ensuring patients receive proper guidance and care.
Engaging the patient: patients are taking control of their healthcare through digital technology. Modern pharmacy apps put prescription management at their fingertips, while allowing them to securely track their health data. This digital connection helps pharmacists spot health trends earlier and deliver more personalized care when patients need it most.
"A recent survey found that 82 per cent of people in Canada reported being interested in virtual care appointments, showing yet again how patients are looking for more control of their healthcare journey," explained Batchvarov. "Embracing this type of patient engagement, while providing a platform that keeps personal medical information confidential with the highest data security protocols, is a key way forward in securing the trust of patients."
The newly released 2025 Pharmacy Trends Report sparked valuable discussion at the company's recent Annual Conference in Toronto on April 29, 2025 — a key forum that brought together leaders from the healthcare, pharmacy, insurance and benefits sectors. This year's conference explored a comprehensive approach to connected healthcare, encompassing the pharmacy, physician and public health sectors, while reaffirming our dedication to data-informed and technology-driven solutions for Canada's healthcare ecosystem.
About TELUS HealthTELUS Health is on a mission to become the most trusted wellbeing company in the world by enhancing the overall efficiency of healthcare and championing workplace wellbeing. By integrating advanced healthcare technology with comprehensive employee support services, TELUS Health provides a holistic approach to primary and preventive health and wellbeing enhancing more than 150 million lives across more than 200 countries and territories. Our innovative digital health platforms, including electronic medical records (EMRs) and virtual care solutions, empower healthcare professionals, employers and governments to deliver personalized care efficiently. Our employee wellbeing programs empower individuals by offering extensive support through Employee and Family Assistance Programs (EFAPs), mental health resources, financial counselling and workplace wellness initiatives. At TELUS Health, we are committed to revolutionizing healthcare to ensure people receive the support they need and employees thrive both personally and professionally. Together, let's make the future friendly. For more information please visit: www.telushealth.com.
For media inquiries, please contact:Marielle HossackTELUS Healthmarielle.hossack@telus.com
SOURCE TELUS Health
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/20/c6210.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
TSX futures lifted by gains in metal prices; eyes on US-China trade talks
(Reuters) -Futures for Canada's main stock index rose on Monday, supported by gains in metal prices, as markets await a fresh round of U.S.-China trade talks later in the day. The futures on the S&P/TSX index were up 0.17% at 5:22 a.m. ET (9:22 GMT). All eyes will be on the high-stakes talks in London, where top U.S. and Chinese officials will attempt to defuse tensions that have recently expanded beyond tariffs to export controls over goods and components critical to global supply chains. The discussions follow a rare call last week between U.S. President Donald Trump and Chinese President Xi Jinping. Meanwhile, Beijing signaled interest in improving relations with Canada, as Chinese Premier Li Qiang and Prime Minister Mark Carney talked on a phone call on Friday, according to the Xinhua news agency. In the stock market, shares of metal miners might grab the spotlight as spot silver rose near 1% in the day, while gold and copper prices also edged higher. On the flip side, oil prices slipped on weak China data, but held on to most of last week's gains On Friday, Canada's main stock index rose to a new record high, led by gains in energy and technology shares, as oil prices advanced and U.S. and Canadian jobs data eased investor concerns about a possible recession. This week, global markets will focus on Wednesday's U.S. inflation report, which will shape expectations for Federal Reserve rate cuts. In corporate news, brokerage firm Barclays raised price target on major Canadian banks, including Royal Bank of Canada, Toronto-Dominion Bank and Canadian Imperial Bank. FOR CANADIAN MARKETS NEWS, CLICK ON CODES: TSX market report [.TO] Canadian dollar and bonds report [CAD/] [CA/] Reuters global stocks poll for Canada Canadian markets directory Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Axios
44 minutes ago
- Axios
How animal welfare became a GOP issue
Animal welfare is becoming part of the Trump health team's agenda, as officials press for changes to drug approvals and product evaluations and portray lab animal testing as a symptom of big-government bloat. Why it matters: The effort is the product of a more than decade-long push to elevate animal welfare issues with the political right that now features congressional oversight hearings and threats to cut off taxpayer funding. Case in point: The Food and Drug Administration is phasing out animal testing requirements for antibody therapies and other drugs and telling companies that use other methods that they may receive streamlined product reviews. Health and Human Services Secretary Robert F. Kennedy Jr. and the leaders of the FDA and National Institutes of Health urged Canadian food inspection officials last month to spare hundreds of ostriches infected with bird flu from a planned cull, saying there would be benefit in studying the birds' immune response. Congressional Republicans like Sen. Rand Paul (R-Ky.) have also held hearings on " taxpayer funded animal abuse" and proposed measures that would close down federally funded labs that use animals. Trump had a mixed record on animal welfare issues in his first term. While he signed a federal law outlawing animal cruelty as well as animal fighting, his administration rolled back protections for certain at-risk animals, reversed rules restricting hunting on public lands and even deleted records of animal welfare violations. The FDA's new non-animal testing strategy could accelerate the process for bringing cures to market and give drug and biotech companies more flexibility — though it relies on some still-unproven alternatives like certain AI models. Between the lines: Among those driving the shift is the White Coat Waste Project, a libertarian-leaning group that is targeting what it calls "wasteful and secretive" taxpayer-funded experiments over its ethical concerns around animal testing. Founder Anthony Bellotti, a former Republican congressional staffer, told Axios the group adapted the playbook for cutting off federal funding for Planned Parenthood. Activists "went after the money source, because if you can fund a problem, you can defund it," Bellotti said. "And I said, 'Holy crap, animal testing is virtually all taxpayer-funded.'" The group has portrayed animal experiments as government waste, pointing to studies that show an 85% failure rate in studies that rely on animal models. The group has published controversial investigations of NIH-funded research, claiming taxpayers funded experiments where beagles were "bitten to death by flies" and that former National Institute of Allergy and Infectious Diseases director Anthony Fauci wasted $1 million on painful experiments on the dogs. NIAID has disputed the findings. Zoom in: The shift in framing animal welfare so it appeals to conservatives, including linking it to causes like states' rights, has taken place over many years, said Republican lobbyist Marty Irby. "I use the term creation care a lot ... we have all these things that we talk about: taking care of people, health care, whatever the case may be. But you know, you can't just push animals to the side." Efforts to address factory farming not only overlap with the Make America Healthy Again movement's interest in food quality but with national security concerns, since one of the biggest pork producers, Smithfield Foods, is owned by a Chinese company, Irby pointed out. There also are attempts to tie animal testing back to conservative suspicion over the pandemic response, including subjecting hamsters, rabbits, monkeys and many other animals to infectious disease experiments without pain management. The issue polls highly among voters on both sides of the aisle, Irby said. The other side: Animal testing remains critical to understanding disease progression and evaluating the safety of drugs, vaccines, food additives and household products. Because they're susceptible to many of the same diseases and have shorter life spans, lab animals provide a window into disease processes across several generations. Experts say the solution in the near time likely will involve a combination of animal and non-animal testing. What's next: Bellotti said plans to phase out animal testing don't go far enough, and he's continuing to push for more lab closures. "There's a lot of rhetoric coming out of the NIH that doesn't match reality," he said. "Without a funding cut for animals and labs, without a timetable and a deadline and a commitment to phasing it out ... it's status quo."
Yahoo
an hour ago
- Yahoo
Infrastructure company Ferrovial boosts stake in 407 ETR highway in Canada
Infrastructure company Ferrovial has completed the acquisition of a 3.3% stake in 407 International (407 ETR) from affiliates of AtkinsRéalis Group, consolidating its position in the Canadian toll highway. The company has also exercised its call option to acquire an additional 1.76% of the common shares of 407 ETR, after receiving all necessary approvals. The closing of the call option is scheduled for 11 June 2025. The transactions, which involve the acquisition of corporations controlled by AtkinsRéalis holding the relevant 407 ETR common shares, represent a total investment by Ferrovial of C$1.99bn ($1.45bn) for a 5.06% stake. This investment breaks down to C$1.35bn for the initial 3.30% stake and C$637m for the subsequent 1.76%, with the latter adjusted according to a pre-agreed formula. With these acquisitions, Ferrovial's ownership in the Canadian highway has increased from 43.23% to 48.29%. AtkinsRéalis, in a separate deal, has also finalised the sale of its remaining 1.7% stake in 407 ETR to Canada Pension Plan Investment Board (CPP Investments). Meanwhile, Public Sector Pension Investment Board (PSP Investments) has acquired a 7.51% interest in 407 ETR from CPP Investments. Following these transactions, the ownership structure of 407 ETR has now Ferrovial at 48.29%, CPP Investments and other institutional investors at 44.20%, and PSP Investments at 7.51%. Highway 407 ETR is a 108km toll route in Ontario's Greater Toronto Area, significantly contributing to the reduction of traffic congestion. Ferrovial, since 1999, has been a shareholder of 407 ETR, which is focused on improving mobility in the Greater Toronto Area. In a recent financial update, Ferrovial reported a 19.1% rise in adjusted earnings before interest, taxes, depreciation, and amortisation to €309m for the first quarter of 2025 compared to the same period of last year. "Infrastructure company Ferrovial boosts stake in 407 ETR highway in Canada" was originally created and published by World Construction Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
